HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
•
***
This stock is shown as delisted in our database.
***
If you think this isn't correct then please
let us know
Aimmune Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing treatments to protect children with food allergies from accidental exposure. Aimmune Therapeutics serves customers worldwide.
Market Cap | 2.248 Billion | Shares Outstanding | 65.45 Million | Avg 30-day Volume | 3.406 Million |
P/E Ratio | Dividend Yield | EPS | -4.49 | ||
Price/Sales | 3909.94 | Price cash flow ratio | Price free cash flow ratio | -12.4 | |
Book Value | 2.75 | Price to Tangible Book | 12.53 | Alpha | 0.01 |
Short Interest Ratio | % Short Interest to Float | R-squared | 0.079728 | ||
BETA | 1.74007 | 52-week High/Low | 37.0 / 10.09 | Stddev | 0.26466 |
Q3 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 9 | 1 | 800.0% | 6 (0.39%) | 0 (0.0%) | |
Funds Holding: | 185 | 160 | 15.63% | 61 (4.01%) | 42 (2.73%) | 45.24% |
13F shares: | 43.565 Million | 48.792 Million | -10.71% | 19.409 Million | 13.983 Million | 38.8% |
% Ownership | 66.5614 | 74.5489 | -10.71% | 29.6544 | 21.3648 | 38.8% |
New Positions: | 85 | 25 | 240.0% | 36 | 11 | 227.27% |
Increased Positions | 29 | 71 | -59.15% | 7 | 17 | -58.82% |
Closed Positions | 59 | 22 | 168.18% | 17 | 10 | 70.0% |
Reduced Positions | 50 | 34 | 47.06% | 15 | 9 | 66.67% |
Total Calls | 1.418 Million | 563.904 Thousand | 151.53% | 389.3 Thousand | 176 Thousand | 121.19% |
Total Puts | 1.087 Million | 306.316 Thousand | 254.89% | 553.366 Thousand | 121.8 Thousand | 354.32% |
PUT/CALL Ratio | 0.77 | 0.54 | 42.59% | 1.42 | 0.69 | 105.8% |
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2020-10-13 | 2 | |
|
80,097,147 | 2020-10-13 | 2 | |
|
0 | 2020-10-10 | 2 | |
|
0 | 2020-10-10 | 2 | |
|
0 | 2020-10-10 | 4 | |
|
0 | 2020-10-10 | 2 | |
|
0 | 2020-10-10 | 2 | |
SHEEHY DOUGLAS T. SEE REMARKS |
|
0 | 2020-10-10 | 6 |
ADELMAN DANIEL C MD CHIEF MEDICAL OFFICER |
|
0 | 2020-10-10 | 6 |
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER |
|
0 | 2020-10-10 | 8 |
DALLAS JAYSON DONALD ALEXANDER PRESIDENT AND CEO |
|
0 | 2020-10-10 | 7 |
|
0 | 2020-10-10 | 2 | |
OXTOBY ANDREW CHIEF COMMERCIAL OFFICER |
|
0 | 2020-10-10 | 6 |
|
26,505,494 | 2020-02-07 | 2 | |
ROZENMAN MARY M. SEE REMARKS |
|
13,878 | 2019-12-31 | 0 |
NESTLE HEALTH SCIENCE US HOLDINGS, INC. |
|
11,727,113 | 2018-12-31 | 0 |
BARROWCLIFFE SUSAN E. GENERAL MANAGER, EUROPE |
|
9,375 | 2018-11-19 | 0 |
DILLY STEPHEN GEORGE PRESIDENT AND CEO |
|
447,008 | 2018-06-11 | 0 |
KNAPP JEFFREY H CHIEF OPERATING OFFICER |
|
12,151 | 2018-03-04 | 0 |
|
11,727,113 | 2018-02-26 | 0 | |
|
6,029,785 | 2018-02-22 | 0 | |
DESOUZA WARREN L. CHIEF FINANCIAL OFFICER |
|
20,681 | 2017-04-03 | 0 |
|
6,020,410 | 2016-11-29 | 0 | |
FORESITE CAPITAL MANAGEMENT II, LLC FORESITE CAPITAL FUND II, L.P. FORESITE CAPITAL MANAGEMENT III, LLC |
|
4,902,920 | 2016-08-18 | 0 |
LONGITUDE CAPITAL PARTNERS II, LLC |
|
7,513,134 | 2016-03-29 | 0 |
ELFONT ROBERT MYLES CHIEF MEDICAL OFFICER |
|
299,002 | 2016-02-26 | 0 |
FORESITE CAPITAL MANAGEMENT II, LLC |
|
0 | 2015-08-05 | 0 |
RAFF HOWARD V. CHIEF OPERATING OFFICER |
|
428,575 | 2015-08-05 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |